Table 4.
Pseudomonas aeruginosa Antibiotic Susceptibilities in Inpatient and Outpatient Children Aged 1–17 Years, 1999–2012*
| Antibiotic | % Resistant Isolates (n)† | ||
|---|---|---|---|
| 1999–2003 | 2004–2007 | 2008–2012 | |
| Inpatients | |||
| Amikacin | 13.7 (12 928) | 12.9 (10 990) | 13.2 (7079) |
| Cefepime | 16.5 (10 747) | 18.5 (10 809) | 19.7 (7119) |
| Ceftazidime | 15.7 (14 239) | 19.1 (12 112) | 18.0 (7398) |
| Ciprofloxacin | 13.4 (13 972) | 15.4 (12 231) | 16.2 (7793) |
| Doripenem | 0 (0) | 0 (0) | 27.6 (87) |
| Gentamicin | 23.8 (15 367) | 24.4 (12 803) | 26.1 (7845) |
| Imipenem | 11.7 (13 128) | 15.4 (10 612) | 15.7 (6185) |
| Levofloxacin | 12.4 (9967) | 14.2 (9377) | 16.9 (5221) |
| Meropenem | 10.5 (5539) | 15.5 (7965) | 16.1 (5622) |
| Piperacillin | 12.9 (11 560) | 13.9 (7596) | 16.4 (3164) |
| Piperacillin-tazobactam | 7.9 (9497) | 8.9 (11 180) | 12.5 (7393) |
| Tobramycin | 10.9 (14 430) | 12.5 (12 389) | 14.2 (7640) |
| Outpatients | |||
| Amikacin | 18.4 (15 710) | 20.5 (15 696) | 21.8 (11 648) |
| Cefepime | 11.1 (13 215) | 11.7 (14 692) | 11.9 (10 822) |
| Ceftazidime | 7.3 (17 465) | 8.9 (16 432) | 7.7 (11 816) |
| Ciprofloxacin | 12.8 (17 472) | 14.8 (17 132) | 13.6 (12 687) |
| Doripenem | 0 (0) | 0 (0) | 12.5 (104) |
| Gentamicin | 25.7 (19 616) | 27.0 (171 719) | 28.4 (12 184) |
| Imipenem | 7.3 (15 687) | 9.5 (14 032) | 10.0 (10 503) |
| Levofloxacin | 13.6 (11 037) | 14.2 (11 243) | 13.1 (8252) |
| Meropenem | 5.8 (6491) | 7.5 (10 743) | 7.4 (9342) |
| Piperacillin | 5.9 (14 547) | 7.1 (9040) | 7.4 (4365) |
| Piperacillin-tazobactam | 3.2 (10 975) | 4.2 (15 188) | 4.4 (10 876) |
| Tobramycin | 11.2 (18 316) | 14.9 (16 996) | 17.3 (12 103) |
*Data source was the Surveillance Network Database–USA.
†n indicates the number of isolates tested.